Nafamostat formate salt-13C6

Nafamostat formate salt-13C6

• UNSPSC Description: Nafamostat formate salt-13C6 is the 13C labeled Nafamostat. Nafamostat, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat blocks activation of SARS-CoV-2[1][2][3][4][5].
• Target Antigen: Apoptosis; SARS-CoV; Ser/Thr Protease
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Apoptosis;Metabolic Enzyme/Protease
• Applications: Neuroscience-Neurodegeneration
• Field of Research: Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/nafamostat-formate-salt-13c6.html
• Purity: 95.90
• Solubility: DMSO : 35 mg/mL (ultrasonic;warming)
• Smiles: O=C([13C]1=[13CH][13CH]=[13C](NC(N)=N)[13CH]=[13CH]1)OC2=CC3=CC=C(C(N)=N)C=C3C=C2.[H]C(O)=O.[H]C(O)=O
• Molecular Weight: 445.38
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Ikehara S, et al. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice. Immunology. 1985 Aug;55(4):595-600.|[3]Pak K, et al. Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis. Hinyokika Kiyo. 1988 Jun34(6):1077-81.|[4]Homma S, et al. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Int Immunopharmacol. 2018 Jan54:39-45.|[5]Markus Hoffmann, et al. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother. 2020 Jun 64(6): e00754-20.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, protect from light, stored under nitrogen)
• Clinical Information: No Development Reported